Rivaroxaban as an Antithrombotic Agent in a Patient With ST-Segment Elevation Myocardial Infarction and Left Ventricular Thrombus
Open Access
- 1 January 2017
- journal article
- case report
- Published by SAGE Publications in Journal of Investigative Medicine High Impact Case Reports
- Vol. 5 (1)
Abstract
The incidence of left ventricular (LV) thrombi in the setting of an anterior myocardial infarction has declined significantly since the advent of primary percutaneous coronary intervention coupled with contemporary antithrombotic strategies in ST-segment elevation myocardial infarctions (STE-ACS). Despite oral anticoagulation with the currently accepted, standard-of-care vitamin K antagonist, warfarin, major bleeding complications still arise. Rivaroxaban is a novel, direct oral factor X anticoagulant that has several advantageous properties, which can attenuate bleeding risk. We present a case in which a patient successfully underwent a 3-month course of rivaroxaban in addition to his dual antiplatelet regimen of aspirin and ticagrelor for his STE-ACS and LV thrombus with resultant complete dissolution.Keywords
This publication has 13 references indexed in Scilit:
- Overview of the New Oral AnticoagulantsArteriosclerosis, Thrombosis, and Vascular Biology, 2015
- An open-label, randomized, controlled, multicenter study exploring two treatment strategies of rivaroxaban and a dose-adjusted oral vitamin k antagonist treatment strategy in subjects with atrial fibrillation who undergo percutaneous coronary intervention (PIONEER AF-PCI)American Heart Journal, 2015
- ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevationEuropean Heart Journal, 2012
- Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary EmbolismNew England Journal of Medicine, 2012
- Executive SummaryChest, 2012
- Frequency of Left Ventricular Thrombus in Patients With Anterior Wall Acute Myocardial Infarction Treated With Percutaneous Coronary Intervention and Dual Antiplatelet TherapyThe American Journal of Cardiology, 2010
- Factors Contributing to Increased Platelet Reactivity in People With DiabetesDiabetes Care, 2009
- 2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial InfarctionCirculation, 2008
- A Once-Daily, Oral, Direct Factor Xa Inhibitor, Rivaroxaban (BAY 59-7939), for Thromboprophylaxis After Total Hip ReplacementCirculation, 2006
- Long-term treatment with ximelagatran, an oral direct thrombin inhibitor, persistently reduces the coagulation activity after a myocardial infarctionJournal of Thrombosis and Haemostasis, 2005